{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:05:33Z","timestamp":1791353133138,"version":"4.3.1"},"reference-count":58,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T00:00:00Z","timestamp":1489104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving toward the incorporation of novel and biologically targeted pharmaceuticals with improved disease activity and gentler toxicity profiles compared with conventional chemotherapeutics. Upfront intensive treatment of MCL includes autologous stem cell transplantation (SCT) consolidation aimed at deepening and lengthening disease remission, but subsequent relapse occurs. Maintenance therapy after autologous SCT in patients with MCL in remission features lower-intensity treatments given over extended periods to improve disease outcomes. Targeted drugs are a natural fit for this space, and are the focus of considerable clinical investigation. This review summarizes recent advances in the field and their potential impact on treatment practices for MCL.<\/jats:p>","DOI":"10.3390\/ph10010028","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T09:39:55Z","timestamp":1489138795000},"page":"28","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma"],"prefix":"10.3390","volume":"10","author":[{"given":"Fengting","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA 98195, USA"},{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gopal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA 98195, USA"},{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Graf","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA 98195, USA"},{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"},{"name":"Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2016.1.419","article-title":"Frontline therapy and role of high-dose consolidation in mantle cell lymphoma","volume":"2016","author":"Rule","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): A randomised, open-label, phase 3 trial of the european mantle cell lymphoma network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): Prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Hoster","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.2014.119115","article-title":"The role of targeted treatment in mantle cell lymphoma: Is transplant dead or alive?","volume":"101","author":"Dreyling","year":"2016","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"Chop and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the groupe d'etude des lymphomes de l'adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by beam or beac + autologous stem-cell support: Still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90y-ibritumomab-tiuxetan added to beam\/c in non-cr patients before transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","article-title":"Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: Outcome related to remission pretransplant","volume":"71","author":"Andersen","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the european mcl network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2016.1.437","article-title":"Minimal residual disease in mantle cell lymphoma: Insights into biology and impact on treatment","volume":"2016","author":"Hoster","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission","volume":"22","author":"Cowan","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: Final results of calgb 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.seminhematol.2011.05.002","article-title":"Minimal residual disease detection in mantle cell lymphoma: Technical aspects and clinical relevance","volume":"48","author":"Pott","year":"2011","journal-title":"Seminars Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (prima): A phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern cooperative oncology group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the wisconsin oncology network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13818","article-title":"Phase II trial of r-chop plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: Swog s0601","volume":"172","author":"Till","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of vcr-cvad with maintenance rituximab for untreated mantle cell lymphoma: An eastern cooperative oncology group study (e1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","article-title":"Two years rituximab maintenance vs. Observation after first-line treatment with bendamustine plus rituximab (b-r) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the stil nhl7\u20132008 maintain trial)","volume":"34","author":"Rummel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the german low grade lymphoma study group (glsg)","volume":"23","author":"Lenz","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-hodgkin lymphoma","volume":"103","author":"Horwitz","year":"2004","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/sonc.2002.30143","article-title":"Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma","volume":"29","author":"Mangel","year":"2002","journal-title":"Semin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2013.332","article-title":"Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma","volume":"28","author":"Dietrich","year":"2014","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/annonc\/mdv364","article-title":"Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"26","author":"Graf","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood.V128.22.145.145","article-title":"Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: Final results of the randomized phase 3 lyma trial of the lysa\/goelams group","volume":"128","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clml.2015.11.014","article-title":"90y-ibritumomab-tiuxetan consolidation therapy for advanced-stage mantle cell lymphoma after first-line autologous stem cell transplantation: Is it time for a step forward?","volume":"16","author":"Mondello","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood.V126.23.337.337","article-title":"Bortezomib maintenance (bm) versus consolidation (bc) following aggressive immunochemotherapy and autologous stem cell transplant (asct) for untreated mantle cell lymphoma (mcl): Calgb (alliance) 50403","volume":"126","author":"Kaplan","year":"2015","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.6004\/jnccn.2012.0147","article-title":"Current issues in vaccines for adult patients with hematologic malignancies","volume":"10","author":"Issa","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/17474086.2015.1087844","article-title":"What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?","volume":"8","author":"Chaudhry","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (complement 1): A randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.V128.22.615.615","article-title":"Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-hodgkin lymphoma: Updated results of the gadolin study","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V128.22.6.6","article-title":"Obinutuzumab-based induction and maintenance prolongs progression-free survival (pfs) in patients with previously untreated follicular lymphoma: Primary results of the randomized phase 3 gallium study","volume":"128","author":"Marcus","year":"2016","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (ga101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: Results from the phase II gauguin study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bjh.12769","article-title":"Ofatumumab monotherapy in relapsed\/refractory mantle cell lymphoma\u2014A phase II trial","volume":"165","author":"Furtado","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1158\/1078-0432.CCR-15-0056","article-title":"Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in preclinical models of mantle cell lymphoma","volume":"21","author":"Barth","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.13132","article-title":"Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma","volume":"168","author":"Heinrich","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/bjh.13773","article-title":"High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma","volume":"171","author":"Cassaday","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive nf-kappa b activation in mantle cell lymphoma b cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase ii study of proteasome inhibitor bortezomib in relapsed or refractory b-cell non-hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"Wright","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: Calgb 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","article-title":"Bortezomib-induced peripheral neurotoxicity: An update","volume":"88","author":"Argyriou","year":"2014","journal-title":"Arch. Toxicol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1158\/1535-7163.MCT-13-0156","article-title":"In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: Targeting the immunoproteasome","volume":"12","author":"Zhang","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of b-cell receptor signaling and canonical nf-kappab activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting btk with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/asheducation-2016.1.432","article-title":"Walking a tightrope: Clinical use of ibrutinib in mantle cell lymphoma in the elderly","volume":"2016","author":"Ruella","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase ii mcl-001 (emerge) study","volume":"31","author":"Goy","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in b-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/10\/1\/28\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:30:10Z","timestamp":1760207410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/10\/1\/28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,10]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3]]}},"alternative-id":["ph10010028"],"URL":"https:\/\/doi.org\/10.3390\/ph10010028","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,10]]}}}